Announcements Trials
Browse Landscape

Phase

Phase 2 27Phase 3 9Phase 4 6Phase 2/3 4Phase 1/2 3Phase 1 2Phase NA 1

Status

Completed 9Unknown 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 1Gastrointestinal 1

Conditions

Multiple Myeloma 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 49fludarabine 37Injections 32Gemcitabine 24Paclitaxel 23Cisplatin 21pembrolizumab 19Radiotherapy 19toripalimab 18Carboplatin 17Capecitabine 17Fluorouracil 15Oxaliplatin 13Nivolumab 12Docetaxel 12camrelizumab 11apatinib 11Temozolomide 11Cetuximab 11Bevacizumab 10Irinotecan 9Immunotherapy, Adoptive 9Drug Therapy 9Etoposide 8sintilimab 7Radiosurgery 7Peripheral Blood Stem Cell Transplantation 7Leucovorin 7Ipilimumab 7Indium 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Unknown × Thalidomide × Clear all
NCT02870036 2017-07-14

Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors

Haihe Biopharma Co., Ltd.

Phase 1 Unknown
243 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT02467647 2015-06-10

HLJDT-2016

Wuhan University

Phase 1 Unknown
500 enrolled
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡